Full Press Release Details
Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in
September 15, 8:00 am ET
Sept. 15 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA - News), a leading
provider of vaccines in China, today announced the initiation of clinical trials
in Ukraine for its inactivated hepatitis A vaccine, Healive, in September, 2008.
The trials are being conducted by Biolik Biopharmaceutical Company, a vaccine
manufacturer located in Kharkov, Ukraine to seek regulatory approval in the
Country. Biolik will also market and distribute Healive in Ukraine, which has an
estimated market opportunity of up to $10 million.
clinical trials are expected to enroll approximately 300 adults and 200 children
with dosing and follow-up occurring over a six month period. The Companies
anticipate that it will take approximately nine to twelve months to complete the
trial and receive regulatory approval.
Weidong Yin, Chairman, President and CEO, commented, "As a developer of
world-class vaccines, our strategy has been to provide high quality vaccines to
people around the world. Sinovac is continuing to pursue strategic distribution
partnerships that enable us to enter attractive markets outside of China by
leveraging our GMP-certified manufacturing capabilities, which are capable of
providing low cost, highly scalable production. We look forward to seeing the
Ukrainian market contribute to our sales growth."
is well known in Ukraine and ex-USSR as the manufacturer of many
immunobiological and medicinal products. Its products are delivered to all
regions of Ukraine, Russia and countries of the Commonwealth of Independent
States. Biolik constantly focuses on the modernization of manufacturing and
improvement of technological schemes. Industrial shops and sites that meet
international standards are commissioned annually. Today, Biolik is the only
enterprise in Ukraine that manufactures vaccines for prophylaxis of diphtheria,
tetanus and pertussis. Additional information about Biolik is available on its
website, http://www.biolik.com.ua
Biotech Ltd. is a China-based biopharmaceutical company that focuses on the
research, development, manufacture and commercialization of vaccines that
protect against human infectious diseases. Sinovac's commercialized vaccines
include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu
(influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal
Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional
information about Sinovac is available on its website, http://www.sinovac.com
. To be added to our distribution list, please email: info@sinovac.com.
announcement contains forward-looking statements. These statements are made
under the "safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be identified by words
or phrases such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates" and similar statements. Among other things, the
business outlook and quotations from management in this press release contain
forward-looking statements. Statements that are not historical facts, including
statements about Sinovac's beliefs and expectations, are forward-looking
statements. Forward-looking statements involve inherent risks and uncertainties.
A number of important factors could cause actual results to differ materially
from those contained in any forward- looking statement. Sinovac does not
undertake any obligation to update any forward-looking statement, except as
required under applicable law.
more information, please contact:
Tel: +86-10-8289-0088
Fax: +86-10-6296-6910
Carrington / Janine McCargo
Tel: +1-646-536-7017/7033